Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Prostate Cancer Disparities in Hispanics Using the National Cancer Database.

Publication ,  Journal Article
Del Pino, M; Abern, MR; Moreira, DM
Published in: Urology
July 2022

OBJECTIVES: To evaluate the differences in prostate cancer characteristics and treatment between Hispanic Americans with different countries of origin using the National Cancer Database. METHODS: We performed a retrospective analysis of 54,947 adult Hispanic Americans diagnosed with prostate cancer between 2004 and 2015. Origin was Mexican (N = 7844; 14.3%), South/Central American (N = 4010; 7.3%), Puerto Rican (N = 2938; 5.4%), Cuban (N = 2549; 4.6%), Dominican (N = 1535; 2.8%), Hispanic not specified (N = 36,269; 65.7%). Comparison between characteristics among Hispanic American sub-groups' categories was performed using chi-square and Kruskal-Wallis tests for categorical and continuous variables respectively. RESULTS: Mexicans had overall worse disease at presentation including highest median PSA (7.8 ng/mL), most prevalent T3/T4 stage (6.7%), M1 stage (8.9%), and high-grade Gleason scores (24.0%) when compared to all other Hispanic American groups. Cubans were most likely to receive hormone therapy and radiation therapy and least likely to receive surgical treatment. Compared to Mexicans, Cubans (hazards ratio [HR] = 1.30, 95% confidence interval = [1.16-1.44]) had worse overall survival, while Puerto Ricans (HR = 1.08 [0.95-1.19] had similar overall survival, and Dominicans (HR = 0.63 [0 0.53-0.75]), South/Central Americans (HR = 0.75, [0.66-0.84]) and not specified (HR = 0.84 [0.79-0.91]) had better survival. CONCLUSION: Among Hispanic Americans with different countries of origin, disparities in prostate cancer characteristics, treatment choice, and survival do exist. Mexicans had the least favorable prostate cancer characteristics at presentation. Cubans had the worst overall survival while they were also most likely to receive hormone and/or radiation as first-line treatment. Our analysis demonstrates significant heterogeneity in the Hispanic American population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

July 2022

Volume

165

Start / End Page

218 / 226

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Retrospective Studies
  • Puerto Rico
  • Prostatic Neoplasms
  • Male
  • Humans
  • Hormones
  • Hispanic or Latino
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Del Pino, M., Abern, M. R., & Moreira, D. M. (2022). Prostate Cancer Disparities in Hispanics Using the National Cancer Database. Urology, 165, 218–226. https://doi.org/10.1016/j.urology.2022.02.025
Del Pino, Matthew, Michael R. Abern, and Daniel M. Moreira. “Prostate Cancer Disparities in Hispanics Using the National Cancer Database.Urology 165 (July 2022): 218–26. https://doi.org/10.1016/j.urology.2022.02.025.
Del Pino M, Abern MR, Moreira DM. Prostate Cancer Disparities in Hispanics Using the National Cancer Database. Urology. 2022 Jul;165:218–26.
Del Pino, Matthew, et al. “Prostate Cancer Disparities in Hispanics Using the National Cancer Database.Urology, vol. 165, July 2022, pp. 218–26. Pubmed, doi:10.1016/j.urology.2022.02.025.
Del Pino M, Abern MR, Moreira DM. Prostate Cancer Disparities in Hispanics Using the National Cancer Database. Urology. 2022 Jul;165:218–226.
Journal cover image

Published In

Urology

DOI

EISSN

1527-9995

Publication Date

July 2022

Volume

165

Start / End Page

218 / 226

Location

United States

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Retrospective Studies
  • Puerto Rico
  • Prostatic Neoplasms
  • Male
  • Humans
  • Hormones
  • Hispanic or Latino
  • Adult